Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Basit Öğe Kaydı
dc.contributor.authorKaracin, Cengiz
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorDemirci, Ayse
dc.contributor.authorKeskinkilic, Merve
dc.contributor.authorBaytemur, Naziyet Kose
dc.contributor.authorYilmaz, Funda
dc.contributor.authorSelvi, Oguzhan
dc.date.accessioned2024-02-23T14:27:18Z
dc.date.available2024-02-23T14:27:18Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractBackground There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and >= 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.en_US
dc.identifier.doi10.1186/s12885-023-10609-8
dc.identifier.issn1471-2407
dc.identifier.issue1en_US
dc.identifier.pmid36765293en_US
dc.identifier.scopus2-s2.0-85147894207en_US
dc.identifier.urihttps://doi.org/10.1186/s12885-023-10609-8
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14537
dc.identifier.volume23en_US
dc.identifier.wosWOS:000980043700010en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofBmc Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdvanced Breast Canceren_US
dc.subjectCyclin-Dependent Kinaseen_US
dc.subjectRibocicliben_US
dc.subjectPalbocicliben_US
dc.subjectEverolimusen_US
dc.subjectFulvestranten_US
dc.subjectEndocrine Treatmenten_US
dc.subjectHormonotherapyen_US
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu